IRIS
LODI, Tiziana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.353
AS - Asia 6.069
EU - Europa 4.492
SA - Sud America 826
AF - Africa 274
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 5
Totale 19.029
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.184
SG - Singapore 2.321
CN - Cina 1.798
VN - Vietnam 947
IE - Irlanda 813
IT - Italia 725
SE - Svezia 681
BR - Brasile 647
FI - Finlandia 557
UA - Ucraina 490
HK - Hong Kong 465
DE - Germania 419
FR - Francia 220
ZA - Sudafrica 208
NL - Olanda 191
GB - Regno Unito 151
TR - Turchia 146
CA - Canada 118
RU - Federazione Russa 75
IN - India 64
AR - Argentina 51
BD - Bangladesh 49
IQ - Iraq 45
JP - Giappone 38
BE - Belgio 36
EC - Ecuador 32
MX - Messico 32
ES - Italia 29
CO - Colombia 28
KR - Corea 27
PL - Polonia 21
PH - Filippine 20
UZ - Uzbekistan 19
VE - Venezuela 18
ID - Indonesia 17
PK - Pakistan 17
CL - Cile 16
PY - Paraguay 13
EG - Egitto 12
CI - Costa d'Avorio 11
CZ - Repubblica Ceca 11
MA - Marocco 10
SA - Arabia Saudita 10
TH - Thailandia 10
TW - Taiwan 10
PE - Perù 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
AT - Austria 8
DO - Repubblica Dominicana 8
DZ - Algeria 7
EU - Europa 7
IR - Iran 7
LT - Lituania 7
PT - Portogallo 7
KE - Kenya 6
KZ - Kazakistan 6
RS - Serbia 6
TN - Tunisia 6
AL - Albania 5
AZ - Azerbaigian 5
JO - Giordania 5
NO - Norvegia 5
NP - Nepal 5
BG - Bulgaria 4
CH - Svizzera 4
JM - Giamaica 4
LB - Libano 4
OM - Oman 4
RO - Romania 4
AU - Australia 3
BA - Bosnia-Erzegovina 3
DK - Danimarca 3
KG - Kirghizistan 3
MK - Macedonia 3
NG - Nigeria 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
ET - Etiopia 2
GE - Georgia 2
GY - Guiana 2
IL - Israele 2
KH - Cambogia 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
MY - Malesia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
BO - Bolivia 1
CR - Costa Rica 1
DM - Dominica 1
EE - Estonia 1
GR - Grecia 1
Totale 19.014
Salva come PNG Salva come JPEG
Città #
Singapore 1.108
Dublin 801
Ashburn 795
Chandler 791
San Jose 603
Santa Clara 575
Jacksonville 541
Hong Kong 438
Beijing 415
Dallas 361
Ann Arbor 282
Dearborn 282
Ho Chi Minh City 279
Boardman 235
Hanoi 209
Nanjing 209
Parma 206
Johannesburg 192
Los Angeles 167
Princeton 155
Lauterbourg 137
San Mateo 132
Izmir 123
Wilmington 118
Shanghai 110
New York 109
Toronto 89
Jinan 75
Shenyang 71
São Paulo 65
Hefei 61
Nanchang 61
Helsinki 59
Des Moines 54
Moscow 53
Kunming 52
Munich 51
Woodbridge 50
Hebei 48
Buffalo 43
Haiphong 42
Da Nang 39
Guangzhou 38
Brussels 34
Tianjin 33
Falls Church 30
Jiaxing 30
Council Bluffs 29
Columbus 27
Changsha 26
Dosolo 26
Houston 26
Tokyo 26
Seattle 25
Brooklyn 21
Orem 21
Rio de Janeiro 21
The Dalles 21
Baghdad 20
Phoenix 20
Zhengzhou 20
Amsterdam 19
Frankfurt am Main 19
Redmond 18
Warsaw 18
Atlanta 17
Padova 17
Bremen 16
Can Tho 16
Haikou 16
London 16
Marseille 16
Tashkent 16
Milan 15
Belo Horizonte 14
Biên Hòa 14
Bologna 14
Chennai 14
Fremont 14
Fuzhou 14
Hangzhou 14
Denver 13
Hải Dương 13
Seoul 13
Taizhou 13
Catania 12
Modena 12
Nuremberg 12
Quito 12
Rome 12
San Francisco 12
Abidjan 11
Chicago 11
Norwalk 11
Redwood City 11
Turku 11
Auburn Hills 10
Brasília 10
Guayaquil 10
Jakarta 10
Totale 11.316
Salva come PNG Salva come JPEG
Nome #
Mechanistic insights on the mode of action of an antiproliferative thiosemicarbazone-nickel complex revealed by an integrated chemogenomic profiling study 313
A yeast-based repurposing approach revealed modulation of dNTP pool as a therapeutic target to treat mitochondrial DNA depletion syndromes 213
Yeast, worm, patient’s fibroblasts and zebrafish as models for drug repositioning of molecules targeting POLG-related diseases 203
A chemical genomic approach to characterize the antiproliferative activity of metal based drugsdriven by phenotypic screening in yeast as a model organism 197
DNA polymerase [gamma] and disease: what we have learned from yeast 195
A chemical genomic approach to characterize the antiproliferative activity of metal-based drugs driven by phenotipic screening in yeast as a model organism 194
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 192
Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on Réunion Island 186
Sabotage at the powerhouse? Unraveling the Molecular Target of 2-Isopropylbenzaldehyde Thiosemicarbazone, a Specific Inhibitor of Aflatoxin Biosynthesis and Sclerotia Development in Aspergillus flavus, Using Yeast as a Model System 184
Amino and carboxy-terminal extensions of yeast mitochondrial DNA polymerase assemble both the polymerization and exonuclease active sites 183
Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy 177
A Klaac null mutant of Kluyveromyces lactis is complemented by a single copy of the Saccharomyces cerevisiae AAC1 gene 175
A single nucleotide polymorphism in the DNA polymerase gamma gene of Saccharomyces cerevisiae laboratory strains is responsible for increased mitochondrial DNA mutability 174
Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models 173
Defective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome 171
Characterization of a promoter mutation in the CYP3 gene of S. cerevisiae which cancels regulation by Cyp1p (Hap1p) without affecting its binding site 168
Screening of thiosemicarbazones as antimycotic drugs 167
Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy 165
IMP2, a nuclear gene controlling the mitochondrial dependence of galactose, maltose and raffinose utilization in Saccharomyces cerevisiae. 164
A yeast-based repurposing approach for the treatment of mitochondrial DNA depletion syndromes led to the identification of molecules able to modulate the dNTP pool 164
Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy 163
In vitro evaluation of the activity of thiosemicarbazone derivatives against mycotoxigenic fungi affecting cereals 162
S. cerevisiae carrying a MGM1/OPA1 chimeric gene: a model for the study of dominant optic atrophy and for drug discovery 162
Yeast as a model of mitochondrial dysfunctions: neurodegenerative diseases and cancer. 161
Allelism of IMP1 and GAL2 genes of Saccharomyces cerevisiae 158
The identification of beneficial molecules for mitochondrial diseases: Saccharomyces cerevisiae as powerful model 157
The Power of Yeast in Modelling Human Nuclear Mutations Associated with Mitochondrial Diseases 156
Carbon catabolite repression in Kluyveromyces lactis: isolation and characterization of the KlDLD gene encoding the mitochondrial enzyme D-lactate ferricytochrome c oxidoreductase. 155
Behaviour of Saccharomyces cerevisiae wine strains during adaptation to unfavourable conditions of fermentation on synthetic medium: Cell lipid composition, membrane integrity, viability and fermentative activity 154
Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations 154
Antimycin- and hydroxamate-insensitive respiration in yeast 151
Combined use of Saccharomyces cerevisiae, Caenorhabditis elegans and patient fibroblasts leads to the identification of Clofilium tosylate as a potential therapeutic chemical against POLG-related diseases 151
A yeast-based screening unravels potential therapeutic molecules for mitochondrial diseases associated with dominant ant1 mutations 151
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 150
Investigation of mupirocin susceptibility in bifidobacteria: physiological and genetic insights. 150
Construction and validation of a yeast model system for studying in vivo the susceptibility to stavudine of DNA polymerase gamma allelic variants 149
COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES 149
Dominance of yeast aac2R96H and aac2R252G mutations, equivalent to pathological mutations in ant1, is due to gain of function 148
Cloning and characterization of the lactate-specific inducible gene KlCYB2, encoding the cytochrome b2 of Kluyveromyces lactis 147
Genetic and chemical rescue of the Saccharomyces cerevisiae phenotype induced by mitochondrial DNA polymerase mutations associated with progressive externalophthalmoplegia in humans 147
A variable neurodegenerative phenotype with polymerase gamma mutation 146
Overexpression of DNA Polymerase Zeta Reduces the Mitochondrial Mutability Caused by Pathological Mutations in DNA Polymerase Gamma in Yeast 146
Catabolite repression by galactose in overexpressed GAL4 strains of Saccharomyces cerevisiae 144
Chiral Aminoacid Containing Acyclic Ligands. I. Syntheses and Conformations 143
A steric gate prevents mutagenic dATP incorporation opposite 8-oxo-deoxyguanosine in mitochondrial DNA polymerases 141
A mitochondrial role in pseudohyphal constitutive mutants obtained from a natural Saccharomyces cerevisiae strain 140
Polymorphisms in DNA polymerase γ affect the mtDNA stability and the NRTI-induced mitochondrial toxicity in Saccharomyces cerevisiae 139
Expression of a lipocalin in Pichia pastoris: secretion, purification and binding activity of a recombinant Major Urinary Protein 138
Identification of drugs for the treatment of POLG-related diseases by means of a high throughput drug repurposing approach performed in Saccharomyces cerevisiae 138
Characterization of KlGUT2, a gene of the glycerol-3-phosphate shuttle, in Kluyveromyces lactis 137
DEFECTIVE MITOCHONDRIAL rRNA METHYLTRANSFERASE (MRM2) CAUSES A MELAS-LIKE SYNDROME 137
Carboxylic acids permeases in yeast: two genes in Kluyveromyces lactis.” 136
Construction and validation of a yeast model system for studying in vivo the susceptibility to stavudine of Polg allelic variants 135
Construction of a yeast model system for studying in vivo susceptibility to stavudine of Polg allelic variants 134
The mitochondrial disulfide relay system protein GFER is mutated in autosomal-recessive myopathy with cataract and combined respiratory-chain deficiency. 131
Overexpression of DNA polymerase zeta and Rev1 reduces the mitochondrial mutability caused by pathological mutations in DNA polymerase gamma in yeast. 131
Klaac null mutant in K. lactis is complemented by a single copy of S. cerevisiae “silent” gene AAC1 131
Saccharomyces cerevisiae as a system to discover beneficial molecules for mitochondrial diseases 131
Secretion of human serum albumin from Kluyveromyces lactis over-expressing KlPDI1 and KlERO1 genes 130
LYS2 gene and its mutation in Kluyveromyces lactis 129
Yeast expression of mammalian Onzin and fungal FCR1 suggests ancestral functions of PLAC8 proteins in mitochondrial metabolism and DNA repair 129
Comparative Functional Genomics of glucose repression in laboratory and wine yeasts 128
Efficient clofilium tosylate-mediated rescue of POLG-related disease phenotypes in zebrafish 128
Modeling of pathogenic variants of mitochondrial DNA polymerase: insight into the replication defects and implication for human disease 127
Modification of nuclear gene expression by inhibition of mitochondrial translation during sporulation in MATa/Mata diploids of Saccharomyces cerevisiae. 125
Mutations in AAC2, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in Saccharomyces cerevisiae and affect mitochondrial DNA stability 124
Mutations in AAC2, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in Saccharomyces cerevisiae and affect mitochondrial DNA stability 122
Overexpression of DNA polymerase zeta reduces the mitochondrial mutability caused by pathological mutations in DNA polymerase gamma in yeast. 122
“Expression and structural characterization of a recombinant mouse major urinary protein” 120
Defective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome 120
Zebrafish polg2 knock-out recapitulates human POLG-disorders; implications for drug treatment 119
Saccharomyces cerevisiae, a model system to study the effect of mtDNA polymerase mutations associated with PEO in humans. 119
“Espressione e secrezione di una Major Urinary Protein di topo nel lievito metilotrofo Pichia pastoris” 118
MIG1-dependent and MIG1-independent regulation of GAL gene expression in Saccharomyces cerevisiae: role of IMP2p 116
Structural modification of cuminaldehyde thiosemicarbazone increases inhibition specificity toward aflatoxin biosynthesis and sclerotia development in Aspergillus flavus 116
“Expression of a lipocalin in Pichia pastoris: secretion, purification and binding activity of a recombinant Major Urinary Protein” 115
Construction and characterization of centromeric, episomal and GFP-containing vectors for Saccharomyces cerevisiae prototrophic strains 115
Klaac null mutant in Kluyveromycs lactis is complemented by a single copy of Saccharomyces cerevisiae gene AAC1 115
The power of yeast in modeling human mutations leading to mitochondrial disease 114
Mitmed: a multicenter consortium for the identification and characterization of nuclear genes responsisble for human mitochondrial disorders 114
Elementi regolativi implicati nel processo di repressione /derepressione da glucosio in Kluyveromyces lactis: differenze rispetto a Saccharomyces cerevisiae 113
Effetti fenotipici e funzionali di mutazioni del gene ANT1 responsabili della patologia umana adPEO nel lievito Saccharomyces cerevisiae 112
Il lievito come modello per lo studio di patologie mitocondriali umane 112
Studio del sistema ADP/ATP carrier in Kluyveromyces lactis: effetti fenotipici della distruzione del gene KlAAC e della introduzione del gene ScAAC1 nel mutante derivato. 112
Yeast model for drug discovery: Identification of molecules acting as potential therapeutics for POLG-related diseases 112
Three target genes for the transcriptional activator Cat8p of Kluyveromyces lactis: acetyl coenzyme A synthetase genes KlACS1 and KlACS2 and lactate permease gene KlJEN1 111
Klaac null mutant in K.lactis is complemented by a single copy of S.cerevisiae gene AAC1 110
L'aumento del dosaggio del gene ero1 favorisce la secrezione di proteine ricombinanti in Kluyveromyces lactis 110
FOG1 and FOG2 genes, required for the transcriptional activation of glucose-repressible genes of Kluyveromyces lactis are homologous to GAL83 and SNF1 of Saccharomyces cerevisiae 110
“MAJOR URINARY PROTEINS: STUDIES ON THE BINDING OF FLUORESCENT MOLECULES AND ITS 13C AND 15N ENRICHED EXPRESSION IN PICHIA PASTORIS” 109
Oxygen is required to restore flor strain viability and lipid biosynthesis under fermentative conditions 109
Studio degli effetti fenotipici e funzionali di mutazioni del gene ANT1 responsabili della patologia umana adPEO nel lievito Saccharomyces cerevisae 109
Isolation of DLD gene of Saccharomyces cerevisiae encoding the mitochondrial enzyme D-lactate ferricytochrome c oxidoreductase 107
Galactose transport in Kluyveromyces lactis: a genomic approach 107
Regulation of heat shock response in Saccharomyces cerevisiae. 106
Predicting the contribution of novel POLG mutations to human disease through analysis in yeast model 106
Yeast as a model for drug discovery: Identification of a molecule acting as potential therapeutics for POLG-related diseases 106
Mutation D104G in ANT1 gene: complementation study in Saccharomyces cerevisiae as a model system 105
Modification of nuclear gene expression by inhibition of mitochondrial translation during sporulation in Mata/Mata diploids of S. cerevisiae 105
Effect of erythromycin upon proteins pattern of heat shocked S. cerevisiae. Identification of new classes of heat-shock and heat-stroke products 105
Totale 14.152
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.902
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.902
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021257 0 0 0 0 0 0 0 0 0 41 172 44
2021/2022787 22 16 15 36 25 24 103 120 34 67 50 275
2022/20232.873 312 276 217 220 232 329 28 193 934 18 87 27
2023/20241.028 54 86 33 30 89 241 85 112 15 88 80 115
2024/20253.286 36 176 191 224 385 505 103 132 398 280 237 619
2025/20266.390 581 668 723 644 974 377 833 195 929 466 0 0
Totale 19.262